Paulino Alvarez1, Alexandros Briasoulis2. 1. Department of Medicine, Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA. paulino-alvarez@uiowa.edu. 2. Department of Medicine, Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA.
Abstract
PURPOSE OF REVIEW: Immune system activation plays a central role in heart failure progression. Large-scale immune modulatory clinical trials targeting tumor necrosis factor-α and broad spectrum immune modulation have been negative. The objective of this review is to highlight past, present, and what is in the horizon for the immunomodulation in heart failure with a focus of biologics. RECENT FINDINGS: Strategies targeting interleukin-1 pathway are currently undergoing clinical evaluation and data from pilot studies are promising. The potential of cell therapy for immune modulation is increasingly recognized in clinical trials. Strategies targeting anti-cardiac antibodies such as immunoadsorption and intravenous immunoglobulin have been used in clinical practice with positive outcomes but large pragmatic clinical trials are lacking. The use of an aptamer to block anti-cardiac antibodies is undergoing phase 1 clinical evaluation. Promising targets include inflammasomes, toll-like receptors, chemokines, natural killer cells, and macrophages. Large-scale immune modulatory clinical trials have been negative. Nevertheless, the experience gained from them along with increasing understanding of molecular mechanisms of immune pathophysiology in heart failure is leading to rapid recognition of new therapeutic targets and approaches.
PURPOSE OF REVIEW: Immune system activation plays a central role in heart failure progression. Large-scale immune modulatory clinical trials targeting tumor necrosis factor-α and broad spectrum immune modulation have been negative. The objective of this review is to highlight past, present, and what is in the horizon for the immunomodulation in heart failure with a focus of biologics. RECENT FINDINGS: Strategies targeting interleukin-1 pathway are currently undergoing clinical evaluation and data from pilot studies are promising. The potential of cell therapy for immune modulation is increasingly recognized in clinical trials. Strategies targeting anti-cardiac antibodies such as immunoadsorption and intravenous immunoglobulin have been used in clinical practice with positive outcomes but large pragmatic clinical trials are lacking. The use of an aptamer to block anti-cardiac antibodies is undergoing phase 1 clinical evaluation. Promising targets include inflammasomes, toll-like receptors, chemokines, natural killer cells, and macrophages. Large-scale immune modulatory clinical trials have been negative. Nevertheless, the experience gained from them along with increasing understanding of molecular mechanisms of immune pathophysiology in heart failure is leading to rapid recognition of new therapeutic targets and approaches.
Authors: Veli K Topkara; Kari T Chambers; Kai-Chien Yang; Huei-Ping Tzeng; Sarah Evans; Carla Weinheimer; Attila Kovacs; Jeffrey Robbins; Philip Barger; Douglas L Mann Journal: JCI Insight Date: 2016-04-06
Authors: Lei Wang; Yu-Lin Li; Cong-Cong Zhang; Wei Cui; Xia Wang; Yong Xia; Jie Du; Hui-Hua Li Journal: Cardiovasc Res Date: 2013-11-20 Impact factor: 10.787
Authors: Yasushi Sakata; Jian-Wen Dong; Jesus G Vallejo; Chien-Hua Huang; J Scott Baker; Kevin J Tracey; Osamu Tacheuchi; Shizuo Akira; Douglas L Mann Journal: Am J Physiol Heart Circ Physiol Date: 2006-09-15 Impact factor: 4.733
Authors: Almudena Val-Blasco; María Jose G M Piedras; Gema Ruiz-Hurtado; Natalia Suarez; Patricia Prieto; Silvia Gonzalez-Ramos; Nieves Gómez-Hurtado; Carmen Delgado; Laetitia Pereira; Gemma Benito; Carlos Zaragoza; Nieves Domenech; María Generosa Crespo-Leiro; Daniel Vasquez-Echeverri; Gabriel Nuñez; Eduardo Lopez-Collazo; Lisardo Boscá; María Fernández-Velasco Journal: J Am Coll Cardiol Date: 2017-01-31 Impact factor: 24.094
Authors: Annekathrin Haberland; Martin Holtzhauer; Alice Schlichtiger; Sabine Bartel; Ingolf Schimke; Johannes Müller; Michael Dandel; Peter B Luppa; Gerd Wallukat Journal: Eur J Pharmacol Date: 2016-07-01 Impact factor: 4.432
Authors: Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Daan Ceelen; Adriaan A Voors; Jasper Tromp; Dirk J van Veldhuisen; Kenneth Dickstein; Rudolf A de Boer; Chim C Lang; Stefan D Anker; Leong L Ng; Marco Metra; Piotr Ponikowski; Sylwia M Figarska Journal: Eur J Heart Fail Date: 2022-01-23 Impact factor: 17.349
Authors: Gerardo García-Rivas; Elena Cristina Castillo; Adrian M Gonzalez-Gil; José Luis Maravillas-Montero; Marion Brunck; Alejandro Torres-Quintanilla; Leticia Elizondo-Montemayor; Guillermo Torre-Amione Journal: ESC Heart Fail Date: 2020-06-13